The Alfred Neurology Unit provides a 24 hour emergency general neurology and stroke service. Elective general neurology and video EEG-monitoring patients are admitted Monday to Friday.
The neurophysiology laboratory offers a range of specialised electrophysiology tests to assist in the diagnosis and treatment of neurological conditions.
The tests are performed by a highly experienced and qualified team of scientists, technicians and neurologists.
Please note that in order to make an appointment with our department we must first receive a referral from your doctor including your full name, address and contact number.
Once a referral is received and processed, you will be sent a letter detailing the time and date of your appointment. We provide a service to inpatients and outpatients; including private referrals.
The tests provided include:
The Stroke Unit is a multidisciplinary team specialising in the management of patients who have suffered a stroke or transient ischaemic attack (TIA).
The Stroke Unit is heavily involved in research and is able to provide, with the friendly cooperation of The Alfred's busy Emergency and Radiology departments, access to intravenous thrombolysis for selected patients with stroke.
Movement Disorder program
The Movement Disorders Program incorporates the Parkinson's disease and movement disorders outpatient service, dystonia clinic and tremor analysis laboratory.
The team includes three neurologists, the movement disorders fellow, nurse, physiotherapist and several post-graduate students.
The team sees over 1400 patients each year in the clinic and as in-patients.
The clinical team is linked with the clinical and laboratory research team at the Van Cleef Roet Centre for Nervous Disorders, Monash University.
Clinico-pathological correlations in Parkinson's disease and Parkinsonian syndromes; Genotype-phenotype correlations in Parkinsonian syndromes; Clinical, surgical and pharmacological aspects of Parkinson's disease and Parkinsonism; Biomarkers in Parkinsonism
Recruiting for the following studies:
Dyskinesias in Parkinson's disease
A phase 2 study looking at the effectiveness of a new oral medication used in reducing drug induced involuntary movements in Parkinson's disease. Recruiting patients with Parkinson's disease and dyskinesias.
Identifying the Optimum Target and Predictors of Outcome in Deep Brain Stimulation for Older Patients with Parkinson's Disease
An investigator initiated multicentre study supported by the NHRMC investigating the use of deep brain stimulation surgery in patients older than 67 years. Recruiting patients accepted onto DBS surgical programs with PD and over the age of 67.
Neuroprotection in progressive supranuclear palsy
The only Australian site for a phase 2 multicentre study looking at a novel intranasal medication for treatment of PSP. Recruiting patients with clinically diagnosed PSP.
Biomarkers for Parkinsonism and neurodegeneration
We are investigating the clinical usefulness of measuring protein levels in the cerebrospinal fluid of patients with Parkinson's disease, parkinsonism and dementia to develop a panel of diagnostic tests for these conditions. Recruiting patients with dementia, parkinsonism, PSP, MSA, CBD and Parkinson's disease.
ACUTE STROKE TREATMENT
ANCROD ASP-II (Ancrod in Stroke Program ? II): A Randomised, Double-Blind, Placebo ?Controlled Study Of Ancrod (Viprinex TM) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute, Ischemic Stroke. Sponsor: Neurobiological Technologies, Inc., USA . Protocol No: NTI-ASP-0503 (Currently recruiting)
SECONDARY PREVENTION OF STROKE
PERFORM Prevention of cerebrovascular and cardiac Events of ischaemic origin with teRutroban in patients with a history oF ischemic stroke or tRansient ischemic attack. The PERFORM Study. An international, randomised, double blind, two parallel group study comparing terutroban 30mg o.d administered orally for a 3 year duration (event driven trial). (Currently recruiting)
ROCKET A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multicenter, Event Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 597939) With Adjusted Dose Oral Warfarin for the Prevention of Stroke and Non Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation. (Not currently recruiting - awaiting ethics approval)
ARCH Aortic arch Related Cerebral Hazard
VITATOPS Vitamins To Prevent Stroke: A multicentre, randomised, double-blind, placebo controlled clinical trial examining the efficacy and safety of multi-vitamin therapy in secondary stroke prevention.
PROFESS Prevention Regimen For Effectively avoiding Second Strokes: A double-blind, active and placebo controlled trial of Aggrenox vs. Clopidogrel + aspirin, with and without Micardis (Ends February 2008)
ONTARGET Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial. (Ends November 2007)
TRANSCEND Telmisartan Randomised Assessment in ACE Intolerant Subjects with Cardiovascular Disease (Ends November 2007)
Neurology & Stroke Management and Referral Guidelines
GP_Referral_Neurology_Stroke.pdf (70.4 KB)
Stroke & TIA Referral Form
GPReferralAlfredTIAReferral.pdf (61.3 KB)
|Van Cleef/Roet Centre for Nervous Diseases, Department of Neuroscience, Monash University||Australian and New Zealand Association of Neurologists|
|Neurosciences Victoria||National Stroke Foundation|
|Hunter New England NSW Health - Stroke and TIA||Internet Stroke Center at Washington University|